Nimbus Therapeutics Announces Clinical Progress in Oncology Therapeutic Pipeline and Provides Business Updates ...

The global artificial intelligence in clinical trials market, valued at US$1.20 billion in 2023, is forecasted to grow at a ...

Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

IROS and Halia Therapeutics’ clinical trial will explore a promising new therapy for obesity, specifically designed to ...

US-based Halia Therapeutics’ new therapy will be put to a six-month-long trial that will involve 60 patients with type 2 ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...

The exosome therapies market is expected to experience significant growth due to increased interest in regenerative medicine, cancer treatments, and drug delivery systems. Leading Indications ...

Gilbert, Arizona-- (Newsfile Corp. - January 2, 2025) - A Race Against Blindness, an Arizona-based nonprofit organization, has awarded a $1 million grant to fund research and clinical trials focused ...

Obudanersen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Angelman Syndrome.

Dofetilide is under clinical development by Hyloris Pharmaceuticals and currently in Phase I for Atrial Flutter.

Original research ranges from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative ...